Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing.
NSAIDs
antibiotics
antidepressants
antihypertensive
colon cancer
drug repurposing
metformin
statins
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Sep 2020
23 Sep 2020
Historique:
received:
20
08
2020
revised:
15
09
2020
accepted:
21
09
2020
entrez:
26
9
2020
pubmed:
27
9
2020
medline:
27
9
2020
Statut:
epublish
Résumé
Colorectal cancer is characterized by high incidence worldwide. Despite increased awareness and early diagnosis thanks to screening programmes, mortality remains high, particularly for patients with metastatic involvement. Immune checkpoint inhibitors or poly (ADP-ribose) polymerase (PARP)-inhibitors have met with disappointing results when used in this setting, opposed to other malignancies. New drugs with different mechanisms of action are needed in this disease. Drug repurposing might offer new therapeutic options, as patients with metastatic colorectal cancer often share risk factors for other chronic diseases and thus frequently are on incidental therapy with these drugs. The aim of this review is to summarise the published results of the activity of drugs used to treat chronic medications in patients affected by colorectal cancer. We focused on antihypertensive drugs, Non-Steroid Anti-inflammatory Drugs (NSAIDs), metformin, antidepressants, statins and antibacterial antibiotics. Our review shows that there are promising results with beta blockers, statins and metformin, whereas data concerning antidepressants and antibacterial antibiotics seem to show a potentially harmful effect. It is hoped that further prospective trials that take into account the role of these drugs as anticancer medications are conducted.
Identifiants
pubmed: 32977434
pii: cancers12102724
doi: 10.3390/cancers12102724
pmc: PMC7598185
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Br J Cancer. 2012 Apr 10;106(8):1374-8
pubmed: 22421948
Cancer Causes Control. 2012 Dec;23(12):1959-64
pubmed: 23065071
Cochrane Database Syst Rev. 2014 Nov 21;(11):CD002745
pubmed: 25415374
Blood Rev. 2016 Jan;30(1):11-9
pubmed: 26219246
BMC Med. 2014 Feb 13;12:28
pubmed: 24521426
World J Gastrointest Oncol. 2014 Jan 15;6(1):11-21
pubmed: 24578784
Int J Cancer. 2011 Jan 1;128(1):227-32
pubmed: 20232382
Lancet Oncol. 2016 Apr;17(4):475-483
pubmed: 26947328
PLoS One. 2014 Nov 06;9(11):e112201
pubmed: 25375154
J Glob Oncol. 2018 Jul;4:1-10
pubmed: 30084749
World J Gastroenterol. 2014 Feb 21;20(7):1858-70
pubmed: 24587664
Ann Oncol. 2009 Feb;20(2):227-30
pubmed: 18842611
Exp Mol Med. 2020 Feb;52(2):281-292
pubmed: 32080340
Cancer Res. 2009 Oct 1;69(19):7775-83
pubmed: 19738039
Curr Drug Metab. 2012 Nov;13(9):1313-22
pubmed: 22493984
Cancer Res. 2007 Jun 1;67(11):5061-3
pubmed: 17545579
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Br J Surg. 2019 Mar;106(4):477-483
pubmed: 30259967
Lancet Oncol. 2011 Jan;12(1):65-82
pubmed: 21123111
Sci Rep. 2017 Apr 05;7:45703
pubmed: 28378839
Trends Mol Med. 2016 Jun;22(6):458-478
pubmed: 27178527
Int J Cancer. 2005 Apr 20;114(4):643-7
pubmed: 15578694
Cancer Causes Control. 2014 Feb;25(2):237-49
pubmed: 24265089
J Affect Disord. 2017 Jan 01;207:353-358
pubmed: 27744223
Transl Oncol. 2020 Feb;13(2):383-392
pubmed: 31896527
Asian J Pharm Sci. 2019 Jan;14(1):30-39
pubmed: 32104436
Dig Dis Sci. 2016 Jan;61(1):255-64
pubmed: 26289256
PLoS One. 2012;7(7):e38886
pubmed: 22808019
Cancer Epidemiol. 2019 Feb;58:52-62
pubmed: 30472477
J Clin Endocrinol Metab. 2012 Jul;97(7):E1170-5
pubmed: 22563104
N Engl J Med. 2005 May 26;352(21):2184-92
pubmed: 15917383
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2500-2506
pubmed: 31203648
J Innate Immun. 2011;3(4):374-82
pubmed: 21411974
Am J Cardiol. 2005 Sep 5;96(5A):24F-33F
pubmed: 16126020
PLoS One. 2011 Jan 27;6(1):e16393
pubmed: 21297998
Mol Cell Oncol. 2015 Feb 11;2(2):e975080
pubmed: 27308430
Clin Gastroenterol Hepatol. 2016 Jul;14(7):973-9
pubmed: 26905907
J Natl Cancer Inst. 2015 Mar 13;107(6):djv045
pubmed: 25770147
Bull Cancer. 2018 Feb;105(2):171-180
pubmed: 29153543
Pharmacol Rev. 2012 Jan;64(1):102-46
pubmed: 22106090
Aging (Albany NY). 2020 Jan 6;12(1):611-627
pubmed: 31905343
Pharmacology. 2008;81(2):164-72
pubmed: 18025841
Clin Ther. 2003 Feb;25(2):342-95
pubmed: 12749503
Bull Acad Natl Med. 2002;186(2):421-43; discussion 443-5
pubmed: 12145848
Clin Sci (Lond). 2009 Nov 23;118(5):315-32
pubmed: 19922415
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Cancer. 2000 Jul 1;89(1):165-70
pubmed: 10897013
Trends Immunol. 2012 Sep;33(9):459-66
pubmed: 22677185
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):892-898
pubmed: 29789327
Int J Cancer. 2017 Jul 1;141(1):62-71
pubmed: 28370155
J Cell Mol Med. 2019 Feb;23(2):1106-1115
pubmed: 30421568
Am J Epidemiol. 2019 Aug 1;188(8):1512-1528
pubmed: 31062847
PLoS One. 2012;7(11):e50043
pubmed: 23209640
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Anticancer Res. 2014 Sep;34(9):5043-50
pubmed: 25202089
Eur J Intern Med. 2016 Oct;34:11-20
pubmed: 27344083
Pharmaceuticals (Basel). 2012 Dec 05;5(12):1346-71
pubmed: 24281340
J Hypertens. 2011 Apr;29(4):623-35
pubmed: 21358417
Front Immunol. 2020 Jan 24;10:3082
pubmed: 32038628
Cell. 2018 Nov 1;175(4):1059-1073.e21
pubmed: 30270039
Cancer Treat Rev. 2014 Sep;40(8):934-41
pubmed: 24997679
Br J Cancer. 2011 Jan 4;104(1):188-92
pubmed: 20877356
Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1039-49
pubmed: 18780400
J Clin Oncol. 2007 Aug 10;25(23):3462-8
pubmed: 17687150
Mol Cell Biol. 1985 Aug;5(8):1969-76
pubmed: 3837853
Lancet Oncol. 2006 Apr;7(4):301-8
pubmed: 16574545
Clin Colorectal Cancer. 2017 Mar;16(1):38-43
pubmed: 27576095
Am J Physiol Cell Physiol. 2017 Feb 1;312(2):C176-C189
pubmed: 27903583
Exp Clin Endocrinol Diabetes. 2020 Apr;128(4):255-262
pubmed: 30149418
Cancer Prev Res (Phila). 2011 Nov;4(11):1808-15
pubmed: 21680706
Sci Rep. 2019 Sep 19;9(1):13560
pubmed: 31537841
Front Endocrinol (Lausanne). 2019 Jan 21;9:807
pubmed: 30719023
Cancer Discov. 2012 Sep;2(9):778-90
pubmed: 22926251
Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52
pubmed: 5246932
ISME J. 2012 Feb;6(2):320-9
pubmed: 21850056
Crit Rev Oncol Hematol. 2013 Nov;88(2):272-83
pubmed: 23806981
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416208
Cancer Med. 2018 May;7(5):2003-2012
pubmed: 29624892
Cancer Prev Res (Phila). 2020 Feb;13(2):203-212
pubmed: 31818851
Oncotarget. 2017 May 5;8(34):57316-57326
pubmed: 28915672
Am J Physiol Cell Physiol. 2014 Jan 15;306(2):C80-8
pubmed: 24133063
Int J Cancer. 2010 Jan 1;126(1):285-96
pubmed: 19739257
Arch Intern Med. 2000 Aug 14-28;160(15):2363-8
pubmed: 10927735
Int J Oncol. 2008 Aug;33(2):277-86
pubmed: 18636148
Medicine (Baltimore). 2015 Jun;94(24):e719
pubmed: 26091452
Tumour Biol. 2016 Feb;37(2):1727-38
pubmed: 26314861
Epidemiology. 2019 Nov;30(6):867-875
pubmed: 31348009
Cancer. 2014 Apr 15;120(8):1178-86
pubmed: 24415516
Life Sci. 2019 Sep 15;233:116680
pubmed: 31344431
J Biochem Mol Toxicol. 2020 Feb;34(2):e22433
pubmed: 31916655
Psychooncology. 2019 Apr;28(4):750-758
pubmed: 30703275
Oncol Rep. 2015 May;33(5):2513-20
pubmed: 25812650
Toxicol Sci. 2011 Jul;122(1):1-6
pubmed: 21507989
Reprod Biomed Online. 2007 Nov;15(5):566-81
pubmed: 18028750
Sci Signal. 2015 Mar 31;8(370):re4
pubmed: 25829448
Br J Cancer. 2011 Jan 4;104(1):193-7
pubmed: 21081933
EBioMedicine. 2019 Oct;48:301-315
pubmed: 31594750
Gut. 2019 Nov;68(11):1971-1978
pubmed: 31427405
Cell Signal. 2015 Sep;27(9):1781-8
pubmed: 26004136
Eur J Pharmacol. 2019 Aug 15;857:172441
pubmed: 31181210
Eur J Pharmacol. 2006 Jul 10;541(1-2):17-23
pubmed: 16753142
Biomed Pharmacother. 2018 Dec;108:184-193
pubmed: 30219675
Biophys J. 2002 Aug;83(2):836-48
pubmed: 12124268
Gut. 2010 Nov;59(11):1572-85
pubmed: 20660702
Cancer Med. 2019 Jun;8(6):3305-3313
pubmed: 31069997
Br J Cancer. 2004 Feb 9;90(3):635-7
pubmed: 14760377
Nat Rev Clin Oncol. 2012 Apr 03;9(5):259-67
pubmed: 22473097
Eur Neuropsychopharmacol. 2015 Aug;25(8):1147-57
pubmed: 25934397
Cancer J. 2014 May-Jun;20(3):225-31
pubmed: 24855012
Br J Cancer. 2015 Nov 17;113(10):1421-6
pubmed: 26505681
Clin Transl Oncol. 2020 Sep;22(9):1651-1656
pubmed: 32008218
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769417
Oncotarget. 2017 Apr 18;8(16):26448-26459
pubmed: 28103573
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1111-4
pubmed: 19623565
Br J Cancer. 2015 Oct 20;113(8):1133-9
pubmed: 26372700